Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | LEGN |
---|---|---|
09:32 ET | 6286 | 45.86 |
09:34 ET | 750 | 46.22 |
09:36 ET | 562 | 46.23 |
09:38 ET | 1800 | 45.875 |
09:39 ET | 1300 | 46.205 |
09:41 ET | 200 | 46.27 |
09:43 ET | 4984 | 46.59 |
09:45 ET | 1125 | 46.71 |
09:48 ET | 1569 | 46.47 |
09:50 ET | 300 | 46.435 |
09:52 ET | 300 | 46.32 |
09:54 ET | 900 | 46.14 |
09:56 ET | 1200 | 45.91 |
09:57 ET | 388 | 46.06 |
09:59 ET | 8390 | 45.725 |
10:01 ET | 100 | 45.735 |
10:03 ET | 1795 | 45.5 |
10:06 ET | 2517 | 45.67 |
10:08 ET | 11910 | 45.455 |
10:10 ET | 300 | 45.36 |
10:12 ET | 2322 | 45.535 |
10:14 ET | 400 | 45.68 |
10:15 ET | 1000 | 45.76 |
10:17 ET | 700 | 45.8 |
10:19 ET | 800 | 45.83 |
10:21 ET | 600 | 45.82 |
10:24 ET | 100 | 45.84 |
10:26 ET | 800 | 45.81 |
10:28 ET | 2999 | 45.86 |
10:30 ET | 200 | 45.825 |
10:32 ET | 200 | 45.8 |
10:33 ET | 200 | 45.83 |
10:35 ET | 700 | 45.87 |
10:37 ET | 5408 | 45.8 |
10:39 ET | 4240 | 45.855 |
10:42 ET | 193 | 45.85 |
10:44 ET | 6450 | 45.89 |
10:46 ET | 1356 | 46.03 |
10:48 ET | 1600 | 46.0125 |
10:50 ET | 640 | 46.06 |
10:51 ET | 100 | 45.995 |
10:53 ET | 2123 | 46.045 |
10:55 ET | 500 | 46.1 |
10:57 ET | 200 | 46.17 |
11:00 ET | 100 | 46.16 |
11:02 ET | 820 | 46.08 |
11:04 ET | 822 | 46.14 |
11:06 ET | 100 | 46.14 |
11:08 ET | 1100 | 46.135 |
11:09 ET | 200 | 46.19 |
11:11 ET | 280 | 46.18 |
11:13 ET | 200 | 46.205 |
11:15 ET | 100 | 46.15 |
11:18 ET | 400 | 46.18 |
11:20 ET | 200 | 46.22 |
11:22 ET | 750 | 46.14 |
11:24 ET | 700 | 46.1289 |
11:26 ET | 100 | 46.14 |
11:29 ET | 3691 | 46.145 |
11:31 ET | 223 | 46.19 |
11:33 ET | 100 | 46.22 |
11:38 ET | 500 | 46.25 |
11:40 ET | 1221 | 46.44 |
11:42 ET | 1800 | 46.31 |
11:44 ET | 400 | 46.35 |
11:47 ET | 2900 | 46.6 |
11:49 ET | 2955 | 46.85 |
11:51 ET | 800 | 46.88 |
11:54 ET | 900 | 46.785 |
11:58 ET | 1890 | 46.62 |
12:00 ET | 500 | 46.55 |
12:02 ET | 200 | 46.5 |
12:03 ET | 2348 | 46.52 |
12:07 ET | 100 | 46.53 |
12:09 ET | 1600 | 46.41 |
12:12 ET | 2343 | 46.46 |
12:14 ET | 350 | 46.44 |
12:16 ET | 1000 | 46.48 |
12:18 ET | 200 | 46.5 |
12:20 ET | 400 | 46.49 |
12:21 ET | 400 | 46.515 |
12:23 ET | 832 | 46.515 |
12:25 ET | 300 | 46.48 |
12:27 ET | 1684 | 46.415 |
12:30 ET | 1169 | 46.43 |
12:32 ET | 2200 | 46.38 |
12:34 ET | 1560 | 46.2539 |
12:36 ET | 300 | 46.17 |
12:38 ET | 200 | 46.14 |
12:39 ET | 530 | 46.2133 |
12:41 ET | 3000 | 46.17 |
12:43 ET | 200 | 46.21 |
12:45 ET | 800 | 46.225 |
12:48 ET | 3340 | 46.185 |
12:50 ET | 200 | 46.2 |
12:52 ET | 200 | 46.18 |
12:54 ET | 1300 | 46.22 |
12:56 ET | 700 | 46.23 |
12:57 ET | 100 | 46.22 |
12:59 ET | 1800 | 46.175 |
01:01 ET | 400 | 46.2 |
01:03 ET | 1100 | 46.245 |
01:06 ET | 2294 | 46.19 |
01:08 ET | 700 | 46.12 |
01:10 ET | 1257 | 46.15 |
01:14 ET | 900 | 46.2 |
01:15 ET | 100 | 46.19 |
01:17 ET | 300 | 46.24 |
01:19 ET | 200 | 46.21 |
01:21 ET | 700 | 46.255 |
01:24 ET | 3989 | 46.245 |
01:26 ET | 1396 | 46.15 |
01:28 ET | 100 | 46.13 |
01:30 ET | 1403 | 46.21 |
01:32 ET | 500 | 46.18 |
01:33 ET | 200 | 46.18 |
01:35 ET | 800 | 46.185 |
01:37 ET | 1550 | 46.24 |
01:39 ET | 800 | 46.205 |
01:42 ET | 171 | 46.17 |
01:44 ET | 1019 | 46.25 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Legend Biotech Corp | 8.4B | -17.8x | --- |
Ascendis Pharma A/S | 7.8B | -14.1x | --- |
Blueprint Medicines Corp | 6.8B | -22.9x | --- |
Insmed Inc | 10.1B | -13.0x | --- |
Vaxcyte Inc | 8.3B | -18.3x | --- |
Intra-Cellular Therapies Inc | 7.3B | -60.0x | --- |
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.4B |
---|---|
Revenue (TTM) | $342.8M |
Shares Outstanding | 182.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.11 |
EPS | $-2.60 |
Book Value | $6.88 |
P/E Ratio | -17.8x |
Price/Sales (TTM) | 24.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -157.97% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.